CClinicalTrials.gg
CompletedNCT01877564Updated Oct 25, 2017Results posted

A Randomized Pilot Study to Evaluate the Effects of a Short Course of Metformin Versus No Therapy in the Period Prior to Hysterectomy for Grade 1-2 Adenocarcinoma of the Endometrium in Obese Non-Diabetic Women

A Phase 2 interventional study of Metformin in Adenocarcinoma of the Endometrium, sponsored by University of Arkansas. Completed at 1 site in United States. Open to female participants aged 45 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-10-25.

Sponsored by University of Arkansas · Phase 2, Interventional, and Treatment

Phase
Phase 2
Study type
Interventional
Enrollment
10
Allocation
Randomized
Ages
45 Years to 65 Years
Sex
Female
01

Study summary

The purpose of this research is to determine the effects of Metformin, a well tolerated drug widely prescribed for treatment of Type 2 Diabetes Mellitus, on endometrium cancer patients.

02

Conditions studied

  • Adenocarcinoma of the Endometrium
03

In context

Adenocarcinoma

2,004 studies on the registry are indexed under Adenocarcinoma; 374 are open to participants now.

This study's enrollment of 10 is below the median of 45 across 1,553 interventional studies indexed under Adenocarcinoma.

Browse Adenocarcinoma studies →

Lead sponsor

University of Arkansas is the lead sponsor of 391 studies on the registry; 39 are open to participants now.

Of its 37 completed or terminated interventional studies of FDA-regulated products, 34 (92%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
45 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • Histological confirmed diagnosis of grade I or II adenocarcinoma of the endometrium
  • Must be obese as defined by a body mass index (BMI) greater than or equal to 30 kg/m2
  • Candidate for surgical removal of their uterus as part of their endometrial cancer treatment
  • Subjects must have signed informed consent
  • Age 42 - 65 years of age
  • Electrocorticogram (ECOG) Performance status of 0 - 2
  • History of adequate renal, liver, and bone marrow function:

    • Hb: (adequate for surgical intervention, with transfusion if necessary) White Blood Cell (WBC): (normal range)
    • Platelets: (180K/cmm)
    • Liver Function Test(LFTs): Normal bilirubin (\<2.0mg/dL), AST/ALT (2xULN)
    • Renal function: creatinine less than 1.4
  • Female subjects must either not be of child-bearing potential or must have a negative urine pregnancy test within 7 days of randomization to Metformin. Subjects are considered not of child-bearing potential if they are surgically sterile or they are postmenopausal for greater than 12 months.

Exclusion criteria

Exclusion Criteria:

  • Poorly differentiated cancer or any of the high-risk subtypes of endometrial cancer including serous, clear cell, or carcinosarcoma
  • History of diabetes mellitus Type 1 or Type 2.
  • Receiving metformin prior to enrollment
  • Known hypersensitivity to metformin.
  • Unable to swallow and retain oral medication.
  • Pregnant or lactating.
  • Previous or concurrent malignancies, except non-melanoma skin cancers, unless curatively treated and with no evidence of recurrence for > 5 years
  • If the physician feels that the candidate is not suitable for the study, he/she will be excluded.
  • Currently taking biguanides, sulfonylurea drugs, thiazolidinediones, insulin, or mTOR or DPP-4 inhibitors or having taken any of these medications during the 12 weeks prior to study participation.
  • Clinical symptoms of gastrointestinal obstruction or bleeding and consideration for immediate surgery or immediate neoadjuvant chemoradiation.
  • History of lactic or other metabolic acidosis.
  • Uncontrolled infectious disease.
  • History of positivity for human immunodeficiency virus (HIV).
  • History of congestive heart failure requiring pharmacologic treatment.
  • History of excessive alcohol abuse, defined by a habitual intake of more than three drinks daily.
  • Mal-absorption syndrome, disease affecting gastrointestinal function, or previous resection of the stomach or small bowel.
  • Current use of medications for weight loss.
  • Currently taking cimetidine, thiazide diuretics or cephalexin. If a patient needs some of these agents, alternative agents should be substituted.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Group 1 - Metformin

    oral metformin at 500 mg twice a day for 14-21 days followed by surgery

    Drug: Metformin

  • No intervention
    Group 2 - No treatment

Interventions

  • DrugMetformin
06

What researchers measure

Primary outcomes

  1. IHC-based Tissue Markers of Proliferation

    Time frame: 1 year

07

Results

Posted Oct 25, 2017

Participant flow

Participants were recruited from the UAMS Gynecologic Oncology Clinic between August 2013 and July 2016.

Participant flow — Overall Study
MilestoneGroup 1 - MetforminGroup 2 - No Treatment
Started64
Completed64
Not completed00

Outcome measures

PrimaryIHC-based Tissue Markers of Proliferation
Time frame:
1 year

No measurements were reported for this outcome.

Adverse events

Collected over 3 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group 1 - Metformin0/6 (0%)0/6 (0%)1/6 (16.7%)
Group 2 - No Treatment0/4 (0%)0/4 (0%)0/4 (0%)
Most frequent other events
Most frequent other events
EventGroup 1 - MetforminGroup 2 - No Treatment
dysuriaRenal and urinary disorders1/60/4

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Group 1 - MetforminGroup 2 - No TreatmentTotal
<=18 years000
Between 18 and 65 years448
>=65 years202
Age, Continuous
Age, Continuous(years)Group 1 - MetforminGroup 2 - No TreatmentTotal
Mean60.6 (42 to 72)61 (58 to 63)60.8 (42 to 72)
Sex: Female, Male
Sex: Female, Male(Participants)Group 1 - MetforminGroup 2 - No TreatmentTotal
Female6410
Male000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Group 1 - MetforminGroup 2 - No TreatmentTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American101
White538
More than one race000
Unknown or Not Reported011
Region of Enrollment
Region of Enrollment(Participants)Group 1 - MetforminGroup 2 - No TreatmentTotal
United States6410
08

Study locations

1 site
  • University of Arkansas for Medical Sciences
    Little Rock, Arkansas 72205, United States
09

References and documents

Study documents

  • Study protocol · May 24, 2016
  • Statistical analysis plan · May 24, 2016

Documents are hosted by the registry — open the source record to download them.

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 25, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01877564
Lead sponsor
University of Arkansas
Responsible party
Sponsor
First posted
Jun 13, 2013
Start date
Aug 29, 2013
Primary completion
Aug 10, 2016
Completion
Jul 10, 2017
Results posted
Oct 25, 2017
Last update
Oct 25, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion